A initiative to create point-of-care gene sequencing is already generating excitement since it would remove the need to send samples via the pricy, time-consuming, and ineffective clinical trial process. Companies in the pharmaceutical industry must contend with the difficulty of deploying expensive molecular diagnostic techniques that have restricted diagnostic use, or "subtle differences," which may now be quickly identified. There is a shortage of qualified laboratory personnel who are familiar with and adept at using these technologies. Not all patients are given access to new technology at the right time. The supply chain that moves samples from one clinical lab to another does not yet enable such technologies. The expense of clinical trials remains expensive.